Skip to main content
SpringerLink
Log in
Book cover

Lung Cancer pp 655–670Cite as

Use of Antisense Oligonucleotides for Therapy

Manipulation of Apoptosis Inhibitors for Destruction of Lung Cancer Cells

  • Protocol

  • 652 Accesses

Part of the book series: Methods in Molecular Medicine™ ((MIMM,volume 75))

Abstract

Lung cancer is the second cause of death after cardiovascular diseases and is the major cause of cancer deaths in the Western world. Lung cancer can be divided into two main categories, non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Due to the enormity of the problem of lung cancer throughout the world and the bad prognosis for many subtypes, mainly related to the development of therapy resistance in tumor cells, the need for novel/alternative therapies is immense. Investigations into the development of drug resistance have led to the discovery of many molecular abnormalities in lung cancer cells, including overexpression of the oncogenes ras, myc, c-erbB-2 and bcl-2, and the loss of function of the tumor-suppressor genes Rb, p53, and p16INK4A (1).

This is a preview of subscription content, log in via an institution.

Protocol
USD   49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Springer Nature is developing a new tool to find and evaluate Protocols. Learn more

References

  1. Salgia, R. and Skarin, A. T. (1998) Molecular abnormalities in lung cancer. J. Clin. Oncol. 16, 1207–1217.

    PubMed  CAS  Google Scholar 

  2. Mashima, T., Seimiya, H., Chen, Z., Kataoka, S., and Tsuruo, T. (1998) Apoptosis resistance in tumour cells. Cytotechnology 27, 293–308.

    Article  PubMed  CAS  Google Scholar 

  3. Reed, J. C. (1995) Bcl-2 familiy proteins: regulators of chemoresistance in cancer. Toxicol. Lett. 82/83, 155–158.

    Article  CAS  Google Scholar 

  4. Toft, N. J. and Arends, M. J. (1997) Apoptosis and necrosis in tumours, in Apoptosis and Cancer (Martin, S. J., ed.), Karger Landes Systems, Basel, Switzerland, pp. 25–45.

    Google Scholar 

  5. Antonsson, B. and Martinou, J. C. (2000) The Bcl-2 protein family. Exp. Cell Res. 256, 50–57.

    Article  PubMed  CAS  Google Scholar 

  6. Chao, D. T., Linette, G. P., Boise, L. H., White, L. S., Thompson, C. B., and Korsmeyer, S. J. (1995) Bcl-xL and Bcl-2 repress a common pathway of cell death. J. Exp. Med. 182, 821–828.

    Article  PubMed  CAS  Google Scholar 

  7. Simonian, P. L., Grillot, D. A. M., and Nunez, G. (1997) Bcl-2 and Bcl-xL can differentially block chemotherapy-induced cell death. Blood 90, 1208–1216.

    PubMed  CAS  Google Scholar 

  8. Dosaka-Akita, H., Katabami, M., Hommura, H., Fujioka, Y., Katoh, H., and Kawakami, Y. (1999) Bcl-2 expression in non-small-cell lung cancers: higher frequency of expression in squamous-cell carcinomas with earlier pT status. Oncology 56, 259–264.

    Article  PubMed  CAS  Google Scholar 

  9. Higashiyama, M., Doi, O., Kodama, K., Yokouchi, H., and Tateishi, R. (1996) Bcl-2 oncoprotein expression is increased especially in the portion of small cell carcinoma within the combined type of small cell lung cancer. Tumor Biol. 17, 341–344.

    Article  CAS  Google Scholar 

  10. Pezzella, F., Turley, H., Kuzu, I., Tungekar, M. F., Dunnill, M. S., Pierce, C. B., et al. (1993) Bcl-2 protein in non-small-cell lung carcinoma. he N. Engl. J. Med. 329, 690–694.

    Article  PubMed  CAS  Google Scholar 

  11. Reeve, J. G., Xiong, J., Morgan, J., and Bleehen, N. M. (1996) Expression of apoptosis-regulatory genes in lung tumour cell lines: relationship to p53 expression and relevance to acquired drug resistance. Br. J. Cancer 73, 1193–1200.

    Article  PubMed  CAS  Google Scholar 

  12. Bojes, H. K., Suresh, P. K., Mills, E. M., Spitz, D. R., Sim, J. E., and Kehrer, J. P. (1998) Bcl-2 and Bcl-xL in peroxide-resistant A549 and U87MG Cells. Toxicol. Sci. 42, 109–116.

    PubMed  CAS  Google Scholar 

  13. Monzo, M., Rosell, R., Felip, E., Astudillo, J., Sanchez, J. J., Maestre, J., et al. (1999) A novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognostic marker in non-small cell lung cancers. J. Clin. Oncol. 17, 2100–2104.

    PubMed  CAS  Google Scholar 

  14. Mesner, P., Budihardjo, I., and Kaufmann, S. H. (1997) Chemotherapy-induced apoptosis. Adv. Pharmacol. 41, 461–499.

    Article  PubMed  CAS  Google Scholar 

  15. Sharma, H. W. and Narayanan, R. (1995) The therapeutic potential of antisense oligonucleotides. BioEssays 17, 1055–1063.

    Article  PubMed  CAS  Google Scholar 

  16. Galderisi, U., Di Bernardo, G., Melone, M. A. B., Galano, G., Cascino, A., Giordano, A., and Cipollaro, M. (1999) Antisense inhibitory effect: a comparison between 3′-partial and full phosphorothioate antisense oligonucleotides. J. Cell. Biochem. 74, 31–37.

    Article  PubMed  CAS  Google Scholar 

  17. Crooke, S. T. (1998) Antisense therapeutics. Biotechnol. Genet. Eng. Rev. 15, 121–157.

    PubMed  CAS  Google Scholar 

  18. Crooke, S. T., Lemonidis, K. L., Neilson, L., Griffey, R., Lesnik, E. A., and Monia, B. P. (1995) Kinetic characteristics of Escherichia coli RNase H1: cleavage of various antisense oligonucleotide-RNA duplexes. Biochem. J. 312, 599–608.

    PubMed  CAS  Google Scholar 

  19. Guvakova, M. A., Yakubov, L. A., Vlodavsky, I., Tonkinson, J. L., and Stein, C. A. (1995) Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors and remove it from low affinity binding sites on extracellular matrix. J. Biol. Chem. 270, 2620–2627.

    Article  PubMed  CAS  Google Scholar 

  20. Cooper, S. R., Taylor, J. K., Miraglia, L. J., and Dean, N. M. (1999) Pharmacology of antisense oligonucleotide inhibitors of protein expression. Pharmacol. Therapeut. 82, 427–435.

    Article  CAS  Google Scholar 

  21. Freier, S. M. and Altmann, K. H. (1997) The ups and downs of nucleic acid duplex stability: structure-stability studies on chemically-modified DNA:RNA duplexes. Nucleic Acids Res. 25, 4429–4443.

    Article  PubMed  CAS  Google Scholar 

  22. Kawasaki, A. M., Casper, M. D., Freier, S. M., Lesnik, E. A., Zounes, M. C., Cummins, L. L., et al. (1993) Uniformly modified 2′-deoxy-2′-fluoro phosphorothioate oligonucleotides as nuclease resistant anti-sense compounds with high affinity and specificity for RNA targets. J. Med. Chem. 36, 831–841.

    Article  PubMed  CAS  Google Scholar 

  23. Cooper, S. R., Taylor, J. K., Miraglia, L. J., and Dean, N. M. (1999) Pharmacology of antisense oligonucleotide inhibitors of protein expression. Pharmacol. Therapeut. 82, 427–435.

    Article  CAS  Google Scholar 

  24. Hanecak, R., Brown-Driver, V., Fox, M. C., Azad, R. F., Furusako, S., Nozaki, C., et al. (1996) Antisense oligonucleotide inhibition of hepatitis C virus gene expression in transformed hepatocytes. J. Virol. 70, 5203–5212.

    PubMed  CAS  Google Scholar 

  25. Crooke, S. T. (1998) Molecular mechanisms of antisense drugs: RNase H. Antisense Nucleic Acid Drug Dev. 8, 133–134.

    Article  PubMed  CAS  Google Scholar 

  26. Monia, B. P., Lesnik, E. A., Gonzalez, C., Lima, W. F., McGee, D., Guinosso, C. J., et al. (1993) Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression. J. Biol. Chem. 268, 14514–14522.

    PubMed  CAS  Google Scholar 

  27. Quartin, R. S., Brakel, C. L., and Wetmur, J. G. (1989) Number and distribution of methylphosphonate linkages in oligodeoxynucleotides affect exo-and eno-nuclease sensitivity and ability to form RNase H substrates. Nucleic Acids Res. 17, 7253–7262.

    Article  PubMed  CAS  Google Scholar 

  28. Leech, S. H., Olie, R. A., Gautschi, O., Simões-Wüst, A. P., Tschopp, S., Häner, R., et al. (2000) Induction of apoptosis in lung-cancer cells following bcl-xL anti-sense treatment. Int. J. Cancer 86, 570–576.

    Article  PubMed  CAS  Google Scholar 

  29. Simões-Wüst, A. P., Olie, R. A., Gautschi, O., Leech, S. H., Häner, R., Hall, J., et al. (2000) Bcl-xL antisense treatment induces apoptosis in breast carcinoma cells. Int. J. Cancer 87, 582–590.

    Article  PubMed  Google Scholar 

  30. Gautschi, O., Tschopp, S., Leech, S. H., Olie, R. A., Simões-Wüst, A. P., Baumann, B., et al. (2001) Activity of a novel bcl-2/bcl-xL bispecific antisense oligonucleotide against tumors of diverse histological origins. J. Nat. Cancer Inst. 93, 463–471.

    Article  PubMed  CAS  Google Scholar 

  31. Zangemeister-Wittke, U., Leech, S. H., Olie, R. A., Simões-Wüst, A. P., Gautschi, O., Luedke, G. H., et al. (2000) A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells. Clin. Cancer Res. 6, 2547–2555.

    PubMed  CAS  Google Scholar 

  32. Olie, R. A., Simões-Wüst, A. P., Baumann, B., Leech, S. H., Fabbro, D., Stahel, R. A., and Zangemeister-Wittke, U. (2000) A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res. 60, 2805–2809.

    PubMed  CAS  Google Scholar 

  33. Morgan, D. M. (1998) Tetrazolium (MTT) assay for cellular viability and activity. Methods Mol. Biol. 79, 179–183.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. School of Biological Sciences, The University of Manchester, Manchester, UK

    Siân H. Leech

  2. Division of Medical Oncology, Department of Internal Medicine, University Hospital Zurich, Zurich, Switzerland

    Robert A. Olie & Uwe Zangemeister-Wittke

Authors
  1. Siân H. Leech
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert A. Olie
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Uwe Zangemeister-Wittke
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Children#x2019;s Hospital, Los Angeles, CA

    Barbara Driscoll phd

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Humana Press Inc., Totowa, NJ

About this protocol

Cite this protocol

Leech, S.H., Olie, R.A., Zangemeister-Wittke, U. (2003). Use of Antisense Oligonucleotides for Therapy. In: Driscoll, B. (eds) Lung Cancer. Methods in Molecular Medicine™, vol 75. Humana Press, Totowa, NJ. https://doi.org/10.1385/1-59259-324-0:655

Download citation

  • DOI: https://doi.org/10.1385/1-59259-324-0:655

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-0-89603-920-9

  • Online ISBN: 978-1-59259-324-8

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation